Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Next Previous
Trial Profile

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDC 1421 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors BioLite Inc

    • Most Recent Events

    • 09 Oct 2023 According to an ABVC Biopharma media release, company has plans to initiate an End of Phase II (EOP II) meeting with the FDA.
    • 28 Feb 2020 According to an American BriVision Corporation media release, A Phase II Part II study is expected to follow at the UCSF Medical Center, along with major medical centers in Taiwan, after and subject to successful completion of this Phase II Part I study.
    • 28 Feb 2020 According to an American BriVision Corporation media release, a full clinical study report (CSR) was submitted to the FDA and TFDA on the FDA (on 2019/12/4) and TFDA (on 2019/12/5).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top